Live Stock Coverage: Time to Buy Neos Therapeutics Inc After Making All-Time Low?

Live Stock Coverage: Time to Buy Neos Therapeutics Inc After Making All Time Low?

The stock of Neos Therapeutics Inc (NASDAQ:NEOS) reached all time low today, Oct, 28 and still has $5.32 target or 13.00% below today’s $6.11 share price. This indicates more downside for the $97.88M company. This technical setup was reported by Barchart.com. If the $5.32 PT is reached, the company will be worth $12.72M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 74,515 shares traded hands. Neos Therapeutics Inc (NASDAQ:NEOS) has declined 37.91% since March 28, 2016 and is downtrending. It has underperformed by 42.63% the S&P500.

Analysts await Neos Therapeutics Inc (NASDAQ:NEOS) to report earnings on November, 8. They expect $-1.61 earnings per share, down 159.68% or $0.99 from last year’s $-0.62 per share. After $-1.58 actual earnings per share reported by Neos Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.90% negative EPS growth.

Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage

Out of 4 analysts covering Neos Therapeutics (NASDAQ:NEOS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neos Therapeutics has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Outperform” rating given on Monday, August 17 by BMO Capital Markets. JMP Securities initiated the shares of NEOS in a report on Monday, August 17 with “Market Outperform” rating. RBC Capital Markets maintained Neos Therapeutics Inc (NASDAQ:NEOS) rating on Thursday, November 12. RBC Capital Markets has “Outperform” rating and $33 price target. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29. The rating was initiated by Wells Fargo on Friday, February 19 with “Outperform”. JMP Securities maintained Neos Therapeutics Inc (NASDAQ:NEOS) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $32 price target. On Monday, August 17 the stock rating was initiated by RBC Capital Markets with “Outperform”.

According to Zacks Investment Research, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.”

More important recent Neos Therapeutics Inc (NASDAQ:NEOS) news were published by: Quotes.Wsj.com which released: “News Neos Therapeutics Inc.NEOS” on April 22, 2015, also Globenewswire.com published article titled: “Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla …”, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on September 19, 2016. More interesting news about Neos Therapeutics Inc (NASDAQ:NEOS) was released by: Globenewswire.com and their article: “Neos Therapeutics Announces Pricing of Initial Public Offering” with publication date: July 23, 2015.

NEOS Company Profile

Neos Therapeutics, Inc., incorporated on June 15, 2009, is a pharmaceutical company. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. The Firm has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). The Company’s product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. The Company’s branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. The Company’s modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment